
Verona Pharma to share phase 3 COPD trial data at ATS 2024
Betsy Goodfellow | May 2, 2024 | News story | Medical Communications | COPD, Cardiology, clinical trial, verona pharma
Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including additional analysis from its phase 3 ENHANCE studies which assessed ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD).
According to the press release, ‘pooled analysis demonstrating reductions in the rate and risk of exacerbations with ensifentrine will be presented as part of the ‘Late Breaking Mini Symposium’ designed to highlight new breakthroughs’.
Ensifentrine is a novel selective dual inhibitor of enzymes phosphodiesterase 3 and phosphodiesterase 4 (PDE3 and PDE4) which combines bronchodilator and non-steroidal anti-inflammatory effects into one molecule.
The drug is currently under review by the US Food and Drug Administration (FDA). If approved, the drug could become the first novel inhaled mechanism for COPD maintenance treatment in over two decades.
Frank Sciurba MD, associate professor of medicine at the University of Pittsburgh School of Medicine, US, commented: “These pooled analyses from the ENHANCE studies provide further evidence of ensifentrine’s potential to become an important therapy in a broad population of COPD patients. The substantial reduction in exacerbation rate and risk with ensifentrine is particularly exciting for patients and physicians.”
Betsy Goodfellow
Related Content

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …






